1394019-95-4

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1394019-93-2 C₂₇H₃₅NO₄ 
• 1774-47-6 trimethylsulfoxonium iodide 

Downstream Products

• 1394019-63-6 5-[(R)-2-biphenyl-4-yl-1-(1-carboxycyclopropylmethyl)ethylcarbamoyl]-2H-pyrazole-3-carboxylic acid 
• 1394019-64-7 5-[(R)-1-biphenyl-4-ylmethyl-2-(1-butoxycarbonylcyclopropyl)ethylcarbamoyl]-1H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R7, R8, Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.